Updated on 24 September 2014
Mr Stefan Oschmann has been appointed as the deputy CEO and vice chairman of the executive board
Singapore: With an intent to reorganize roles and separation of activities, German drugmaker, Merck has recently announced that the board of partners has promoted Mr Stefan Oschmann as the deputy CEO and vice chairman of the executive board.
The company further said in a statement that Ms Belen Garijo has been appointed to take over the leadership for the pharma business. As per the announcement, Ms Garijo will take on responsibility for the entire pharma business including consumer health, allergy and biosimilars.
Mr Johannes Baillou, chairman, board of partners, Merck, said, "The changes in the top management will strengthen Merck's leadership team and will help the company reach its ambitious growth targets by 2018."
He mentioned that Mr Oschmann had sucessffully reorganized Merck's business over the past few years and the new role will familiarize him with group-wide functions by assuming external responsibilities for the company.
He added, "Ms Garijo can further develop our business organization and in her future role will provide a significant contribution to ensure the sustainable success of our pharma businesses."